KeViRx, Inc selected as part of BLUE KNIGHT™ collaboration for global health preparedness

Charlottesville, Virginia – KeViRx, Inc. (“KeViRx”) has been selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services.

Blue Knight is a collaborative program designed to anticipate and respond to global health security threats. Blue Knight provides a scientific and technological ecosystem for innovative, early stage startup companies to develop technologies that are strategically aligned with global health interests. KeViRx was selected for this program based on its platform small molecule technology, KVX-053, which displays efficacy in preclinical models of ovarian cancer, acute myeloid leukemia and acute lung injury. As a Blue Knight company with a footprint at JLABS @ Washington, DC, KeViRx will benefit from dedicated mentorship and unique benefits from BARDA, in addition to access to the Johnson & Johnson Innovation extensive global network of innovators for critical insights centering on KVX-053 development.

“KeViRx is honored to be selected to be a Blue Knight company and we are excited to be working with the Blue Knight program. We are optimistic that the program will help advance our KVX-053 platform for global health applications in the present and the future,” said Dr. John S. Lazo, who serves as KeViRx’s Chief Scientific Officer.

Growth of Early-Stage Resident Companies Marks the Third Anniversary of Johnson & Johnson Innovation – JLABS @ Washington, DC

Celebration of the three-year anniversary of JLABS @ Washington, DC (JLABS DC), it’s great timing to highlight recent accomplishments and milestones reached by incubating and regional companies. Additionally, JLABS DC is excited to share new access to specialized lab equipment to support more innovators within the region. Since the start of 2024, there has been …

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide …

07/18/2024

Virginia Companies Expand into Global Markets through Commonwealth’s Trade Accelerator Program

Governor Glenn Youngkin announced that 11 companies across the Commonwealth have graduated from the Virginia Economic Development Partnership’s (VEDP) Virginia Leaders in Export Trade (VALET) program and 14 companies have joined the two-year program. VALET, which now has 402 graduated companies, assists Virginia exporters that have firmly established domestic operations and are committed to international …

News